Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement.

Macabeo, Bérengère; Wilson, Liam; Xuan, Jianwei; Guo, Ruichen; Atanasov, Petar; Zheng, Linda; François, Clement; Laramée, Philippe

Macabeo, Bérengère; Wilson, Liam; Xuan, Jianwei; Guo, Ruichen; Atanasov, Petar; Zheng, Linda; François, Clement; Laramée, Philippe.

Afiliación

Macabeo B; Aix-Marseille Université, Marseille, France.
Wilson L; Pierre Fabre Group, Paris, France.
Xuan J; Health Economics and Market Access, Amaris Consulting, Shanghai, China.
Guo R; Health Economic Research Institute, Sun Yat-Sen University, Guangzhou, China.
Atanasov P; Institute of Clinical Pharmacology, Qilu Hospital of Shandong University, Jinan, China.
Zheng L; Health Economics and Market Access, Amaris Consulting, Barcelona, Spain.
François C; Pierre Fabre Group, Shanghai, China.
Laramée P; Aix-Marseille Université, Marseille, France.

J Mark Access Health Policy ; 11(1): 2218633, 2023.

Article en En | MEDLINE | ID: mdl-37325810

Palabras clave

National Reimbursement Drug List; decision making; health technology assessment; innovative drug access; pricing; reimbursement; risk-sharing

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Health_economic_evaluation / Health_technology_assessment / Prognostic_studies Idioma: En Revista: J Mark Access Health Policy Año: 2023 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google